Talawar Therapeutics to Go Public via Business Combination with JATT II Acquisition Corp

Boundless Bio and Serapha Bio Announce Merger and $230 Million Private Placement

June 25, 2026

Biotechnology

Boundless Bio and Serapha Bio entered into a definitive agreement to merge in an all-stock transaction. Serapha will combine with Boundless Bio, with the combined company expected to operate as Serapha Bio and trade on Nasdaq under ticker AATD, following a pre-closing $230 million private investment led by RA Capital Management and RTW Investments.

Torrent Pharmaceuticals Acquires Controlling Stake in J. B. Chemicals & Pharmaceuticals from KKR

June 29, 2025

Pharmaceuticals

Torrent Pharmaceuticals has agreed to acquire a controlling stake in J. B. Chemicals & Pharmaceuticals from KKR at an equity valuation of INR 25,689 crore, purchasing a 46.39% stake (with potential to aggregate to 49.19%) followed by a mandatory open offer and a planned merger. The deal strengthens Torrent's presence in the Indian pharmaceutical market and adds JB Pharma's CDMO and international capabilities to Torrent's platform.

Air Water Ventures Ltd. to Go Public via Business Combination with Athena Technology Acquisition Corp. II

April 20, 2023

Infrastructure

Air Water Ventures Ltd. entered a definitive agreement to combine with publicly listed SPAC Athena Technology Acquisition Corp. II, creating The Air Water Company. The business combination values Air Water Ventures at a $300 million pre-money equity value and is expected to close in the first quarter of 2024, pending Athena Technology II stockholder approval and regulatory approvals.

OceanTech Acquisitions I Corp and Captura Biopharma Sign Definitive Business Combination Agreement

August 10, 2022

Biotechnology

OceanTech Acquisitions I Corp., a special purpose acquisition company, signed a definitive merger agreement with Captura Biopharma to take the biotech company public. The combined company is expected to operate under the name Captura Biopharma Holdings, Inc. and remain listed on Nasdaq, subject to SEC, regulatory, and stockholder approvals.

Mountain Crest Acquisition Corp II Completes Business Combination with Better Therapeutics

October 29, 2021

Healthcare Services

Mountain Crest Acquisition Corp II completed a business combination with Better Therapeutics, taking the prescription digital therapeutics company public on Nasdaq under the ticker BTTX. The transaction generated approximately $70 million in gross proceeds (including a PIPE led by Farallon Capital Management, RS Investments, Sectoral Asset Management and Monashee Investment Management) and included a contingent credit facility from Hercules Capital to fund clinical development and regulatory efforts for Better Therapeutics' lead product, BT-001.

SAB Biotherapeutics to Go Public via Merger with Big Cypress Acquisition Corp.

October 20, 2021

Biotechnology

SAB Biotherapeutics entered into a definitive business combination/merger agreement with Big Cypress Acquisition Corp. (a SPAC), with the combined company to operate as SAB Biotherapeutics and be listed on Nasdaq. Big Cypress stockholders approved the deal, and the transaction was expected to close on or about October 22, 2021, subject to customary conditions.